[Federal Register Volume 65, Number 116 (Thursday, June 15, 2000)]
[Notices]
[Pages 37563-37564]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-15114]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30DAY-43-00]


Agency Forms Undergoing Paperwork Reduction Act Review

    The Centers for Disease Control and Prevention (CDC) publishes a 
list of information collection requests under review by the Office of 
Management and Budget (OMB) in compliance with the Paperwork Reduction 
Act (44 U.S.C. chapter 35). To request a copy of these requests, call 
the CDC Reports Clearance Officer at (404) 639-7090. Send written 
comments to CDC, Desk Officer; Human Resources and Housing Branch, New 
Executive Office Building, Room 10235; Washington, DC 20503. Written 
comments should be received within 30 days of this notice.

Proposed Projects

    1. Survery of Laboratory Practices for Mycobacterium tuberculosis 
Drug Susceptibility Testing in the U.S.--New--As part of the continuing 
effort to support public health objectives of treatment, disease 
prevention and surveillance programs, the Public Health Practice 
Program Office (PHPPO), Centers for Disease Control and Prevention 
(CDC) seeks to collect information from both public health and private 
sector laboratories performing drug susceptibility testing on 
Mycobacterium tuberculosis. Tuberculosis is a continuing public health 
problem in the United States despite declining case rates. Although 
public health efforts have brought multi drug resistant tuberculosis 
(MDRTB) under control, these MDRTB and other drug resistant isolates 
will continue to challenge laboratory support for TB control because of 
higher prevalence rates and potential for transmission in some segments 
of the U.S. population. To control this health problem, it is 
imperative that cases of tuberculosis are identified and placed on 
effective chemotherapy as quickly as possible. Information collected in 
the survey will be on test methods, drug concentrations, quality 
assurance, quality control and reporting practices. The survey will 
also collect information regarding the type of laboratories where 
testing is performed, the number of tests performed, testing for 
primary or secondary anti-tuberculosis drugs and turnaround time for 
reporting susceptibility test results to the clinician and public 
health programs. This survey will provide CDC with information to 
facilitate standard use of drugs and concentrations tested, 
interpretation of test results, and laboratory reports so that the 
information for the clinician is consistent regardless of the 
laboratory performing testing. This 25-question survey will be mailed 
to 200 laboratories which are directly involved in Mycobacterium 
tuberculosis susceptibility drug testing. The amount of time required 
for completion of the survey will be 30-45 minutes for each respondent. 
The only cost to the respondent is the time involved in completion of 
the survey. Results of the survey will be published in a peer-reviewed 
journal and shared at national meetings to encourage the adoption of 
standard practices. The estimated annualized burden for this project is 
150 hours.

[[Page 37564]]



----------------------------------------------------------------------------------------------------------------
                                                                                   Number of      Average burden
                         Respondents                              Number of        responses/      per response
                                                                 respondents       respondent       (in hours)
----------------------------------------------------------------------------------------------------------------
Laboratories.................................................             200                1            45/60
----------------------------------------------------------------------------------------------------------------


    Dated: June 8, 2000.
Nancy Cheal,
Acting Associate Director for Policy, Planning and Evaluation, Centers 
for Disease Control and Prevention (CDC).
[FR Doc. 00-15114 Filed 6-14-00; 8:45 am]
BILLING CODE 4163-18-P